Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Ramaswamy Govindan(Washington University in St. Louis), Toshiaki Takahashi(Okayama University), Qui Tran(Amgen (United States)), Benjamin Besse(Institut Gustave Roussy), Grace K. Dy(Roswell Park Comprehensive Cancer Center), Martin Schüler(German Cancer Research Center), Alessandra Curioni‐Fontecedro(University of Fribourg), Omar Mather(Amgen (United States)), Bob T. Li(Memorial Sloan Kettering Cancer Center), Gregory Friberg(Amgen (United States)), Alexander I. Spira(Virginia Cancer Specialists), Adrian G. Sacher(Princess Margaret Cancer Centre), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Timothy Price(Basil Hetzel Institute), Abraham Anderson(Amgen (United States)), Vamsidhar Velcheti(Cleveland Clinic), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Haby Henary(Amgen (United States)), Fabrice Barlési(Hôpital Nord), Suresh S. Ramalingam(Emory University), Terufumi Kato(Taipei Veterans General Hospital), Jürgen Wolf(University of Cologne), Agnes Ang(Amgen (United States)), Gataree Ngarmchamnanrith(Amgen (United States)), Hossein Borghaei(Fox Chase Cancer Center)
Cited by 1,783
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k